Home/ImpediMed/Erik Anderson
EA

Erik Anderson

CEO

ImpediMed

ImpediMed Pipeline

DrugIndicationPhase
L‑Dex® AnalysisLymphedema (cancer survivorship)Commercial
BodyComp™ AnalysisBody composition, weight‑management, GLP‑1 therapy monitoringCommercial
HF‑Dex® AnalysisHeart failure fluid managementCommercial